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Background: Recombinant antibodies are highly successful in many different pathological conditions and currently
enjoy overwhelming recognition of their potential. There are a wide variety of protein expression systems available,
but almost all therapeutic antibodies are produced in mammalian cell lines, which mimic human glycosylation.
The production of clinical-grade antibodies in mammalian cells is, however, extremely expensive. Compared to
mammalian systems, protein production in yeast strains such as Pichia pastoris, is simpler, faster and usually results
in higher yields.
Results: In this work, a trivalent single-chain fragment variable (scFv)-based N-terminal trimerbody, specific for the
human carcinoembryonic antigen (CEA), was expressed in human embryonic kidney 293 cells and in Pichia pastoris.
Mammalian- and yeast-produced anti-CEA trimerbody molecules display similar functional and structural properties,
yet, the yield of trimerbody expressed in P. pastoris is about 20-fold higher than in human cells.
Conclusions: P. pastoris is an efficient expression system for multivalent trimerbody molecules, suitable for their
commercial production.
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Over the past decades, there has been growing interest
in the use of recombinant antibodies in bioanalytical and
medical applications [1]. In an attempt to improve the
therapeutic efficacy of antibodies, new recombinant for-
mats with modified properties have been generated [2].
Multivalent and multispecific antibodies capable of sim-
ultaneously blocking multiple growth and survival path-
ways have the potential to meet the current and future
therapeutic challenges, and indeed many of them are ad-
vancing in clinical development [3]. The most common
strategy to create multivalent IgG-like formats has been
the fusion of antibody fragments with homodimerization
sequences (e.g., ZIP miniantibody [4], minibody [5] or* Correspondence: lav@eng.au.dk
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article, unless otherwise stated.single-chain fragment variable (scFv)-Fc antibody [6]). A
different strategy to multimerize antibody fragments is
based on the modification of the interdomain linker
length to generate bivalent, trivalent or tetravalent mole-
cules [7,8]. Other protein-protein interactions have been
also used to create multivalent non-IgG-like formats,
such as the streptavidin-biotin system, the C-terminal
multimerization domain of the tumor-suppressor pro-
tein p53 [9], and the ribonuclease barnase with its in-
hibitor, barstar [10], among others [2].
A variety of expression systems ranging from bacterial
cells to mammalian cells have been used to express
recombinant antibodies [11,12]. E. coli is the most com-
monly used host for the expression of antibody fragments,
whereas mammalian cells are used for the expression of
large, multidomain antibodies such as full-length mono-
clonal antibodies or complex recombinant antibody frag-
ments [13]. In fact, almost all approved therapeuticCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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culture systems [14].
In previous studies, we reported the in vitro and
in vivo characterization of a multivalent antibody gener-
ated by fusing a trimerization (TIE) domain to the C-
terminus of a scFv antibody [15-17]. TIE domains are
composed of the N-terminal trimerization region of col-
lagen XVIII NC1 (TIEXVIII) or collagen XV NC1 (TIEXV)
flanked by flexible linkers. The new antibody format,
termed trimerbody, is trimeric in solution and exhibited
excellent antigen binding capacity and multivalency
[15-17]. Furthermore, by fusing scFv antibodies with the
same or different specificity to both ends of a TIEXVIII
domain, we have produced monospecific or bispecific
hexavalent-binding molecules, expanding the scope of
potential applications of trimerbody molecules [18].
To date, trivalent and hexavalent scFv-based trimerbo-
dies have only been produced in mammalian cell cul-
tures [15-18]. However, the generation of stable
antibody-producing mammalian cell lines is an expen-
sive and time-consuming procedure. Here, we evaluated
the potential of the methylotrophic yeast P. pastoris
[12,19,20] to produce with high yield a N-terminal
trimerbody specific for the human carcinoembryonic
antigen (CEA) [16]. The functional and biochemical
properties of both mammalian- and yeast-derived
trimerbodies were gauged demonstrating the functional
equivalence of the two preparations. Our results demon-
strate that P. pastoris is a viable alternative expression
system for scFv-based N-terminal trimerbody molecules.
Results
Generation of anti-CEA scFv-based N-terminal trimerbody
expression vectors
In this study we have generated a pPICZαA-based vector
for the expression of the MFE-23 scFv-based N-terminal
trimerbody (MFE-23N) in P. pastoris (Figure 1), and we
demonstrated that MFE-23N molecules are efficiently
secreted as soluble proteins by transformed P. pastoris
cells. Western blot analysis shows that under reducingFigure 1 Schematic diagrams showing the genetic and domain struct
representation of gene constructs. Both constructs bear the anti-CEA MFE-2
(hatched box), for subsequent purification and immunodetection. Signal pe
HEK-293 cells (upper) and P. pastoris (lower) respectively. (B) Schematic rep
N-terminal trimerbody.conditions, a single polypeptide chain with mass around
37 kDa was seen (Additional file 1: Figure S1B). As
previously shown [16], the MFE-23N trimerbody is effi-
ciently secreted as soluble functional protein by HEK-
293 cells transfected (Additional file 1: Figure S1A) with
the expression vector pCEP4-MFE-23-NC1ES- (Figure 1).
Secreted MFE-23N trimerbodies from both sources are
able to recognize immobilized human CEA with high
affinity and specificity (Additional file 2: Figure S2).
Purification and functional characterization of yeast- and
mammalian- produced anti-CEA scFv-based N-terminal
trimerbodies
For purification, the extracellular medium of P. pastoris
cells after 72 hours of methanol induction, and the
serum-free conditioned media from stably transfected
HEK-293 cells were independently collected. Both MFE-
23N trimerbodies were purified by immobilized metal
affinity chromatography, which yielded >95% pure
37 kDa proteins as assessed by reducing SDS-PAGE
(Figure 2A). Both systems produced soluble and func-
tional MFE-23N molecules, but with significant differ-
ences in antibody yields from Pichia and HEK-293 cells,
6 and 0.35 mg/l, respectively. Importantly, the yeast-
produced MFE-23N trimerbody was functional and
recognized, as efficiently as the mammalian-produced
MFE-23N trimerbody, human CEA either plastic immo-
bilized (Figure 2B) or expressed on the tumor cell
surface (Figure 2C).
Structural characterization of yeast and mammalian
produced anti-CEA scFv-based N-terminal trimerbodies
Both mammalian- and yeast-produced trimerbodies elute
from the analytical gel-filtration columns as major peaks
at 13 ml with molar masses of 110 or 108 kDa,
respectively. These masses are consistent with the calcu-
lated values for the trimeric molecules (110 and 113 kDa,
respectively) (Figure 3A, B). A minor peak eluting at 11 ml
is also seen in the chromatograms of both molecules, with
molar mass of 214 and 210 kDa (yeast and mammalianure of scFv-based N-terminal trimerbodies. (A) Diagrammatic
3 scFv gene (VH-linker-VL), a TIEXVIII domain and c-myc and His tags
ptides were from oncostatin M (OM) and α-factor for expression in
resentation of the domain structure of the scFv-based
Figure 2 Characterization of purified trimerbodies. (A) Reducing SDS-PAGE of anti-CEA scFv-based N-terminal trimerbody (MFE-23N) purified
from HEK-293 cells or P. pastoris. The functionality of purified MFE-23N trimerbodies is demonstrated by ELISA against plastic immobilized CEA
(B) and by FACS on CEA− and CEA+ tumor cells (C). The anti-CEA C6G9 mAb (IgG) was used as control.
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contain about 10% of the protein (relative to the major
ones as estimated from absorbance at the corresponding
maxima), and their masses are consistent with hexamers
(possibly dimers of the corresponding trimmers). SDS-
PAGE analysis of the two species separated in the gel fil-
tration column showed a single band at the same position
(Additional file 3: Figure S3), and at the expected position
relative to the molecular weight markers (between the
45 kDa and 35 kDa markers, in agreement with the calcu-
lated values of 37 and 38 kDa for the yeast- and mammalian-
produced MFE-23N, respectively). These results demonstrate
that the purified MFE-23N trimerbodies behave predomin-
antly as trimers with a small proportion of hexamers, inde-
pendently of the producer organism.
The CD spectra of both trimerbodies were very similar,
with minima at 217 nm and less negative minima at
228–230 nm (Figure 3C). This is consistent with the
secondary structures of the scFv domain, mainly β-sheet
and irregular loops, plus the contribution of the helical
structures of the trimerization domains of collagen XVIIINC1 domain and the linker sequences (which probably
are flexible random coils). The MFE-23N molecules pro-
duced in P. pastoris and in HEK-293 cells showed a major
cooperative thermal transition, with essentially the same
mid-point denaturation temperature of 48–49°C. At high
temperatures another minor transition is observed,
possibly due to aggregation phenomena of the denatured
polypeptide chains. The same behavior was observed in
experiments recorded at 210 nm with the trimeric mole-
cules separated from hexameric ones by gel filtration
(Figure 3D). These results show that the scFv-based N-
terminal trimerbodies produced in P. pastoris and in
HEK-293 cells have very similar structures and thermal
stabilities.
Serum stability study of yeast and mammalian produced
N-terminal trimerbodies
Both MFE-23N trimerbodies were further analyzed to
evaluate their long-term stability in serum, an important
feature of recombinant antibodies for potential diagnos-
tic or therapeutic applications. For this purpose, purified
Figure 3 Structural characterization of purified trimerbodies. Oligomeric analysis of MFE-23N purified from P. pastoris (A) or HEK-293 cells (B).
Circular dichroism spectrum (C) and thermal denaturation (D) for MFE-23N molecules purified from P. pastoris (red line) and HEK-293 cells
(black line).
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human serum for 0 (control) to 4 days at 37°C (Figure 4).
MFE-23N molecules purified from P. pastoris were more
stable with 60% CEA binding activity after 4 days of
incubation, whereas mammalian-produced MFE-23N
molecules retained around 40% CEA binding activity.
The stability was also analyzed by western blot (Figure 4B),
and we found that after 4 days at 37°C 60% of the
MFE-23N trimerbody produced in P. pastoris was struc-
turally intact, while around 40% of the mammalian-
produced MFE-23N trimerbody was functional at the end
of the assay.
Discussion
In the present study we demonstrate that methylotrophic
yeast P. pastoris secreted functional CEA-specific MFE-23
scFv-based N-terminal trimerbody at significant levels.
Moreover, we demonstrate that both yeast- and
mammalian-produced MFE-23N trimerbodies have similar
functional and structural properties. Purified MFE-23N
molecules were trimeric in solution, as unambiguouslyshown by the light scattering measurements. The anti-
CEA scFv-based N-terminal trimerbodies produced in P.
pastoris and in HEK-293 cells are highly efficient at recog-
nizing antigen either immobilized in plastic, or associated
to the cell surface. The dose-dependent binding curves of
purified MFE-23N molecules to plastic immobilized human
CEA were comparable. Furthermore, both scFv-based N-
terminal trimerbodies specifically recognize CEA cancer
cells. Additionally, we demonstrated that MFE-23N mole-
cules produced in yeast are slightly more stable in human
serum than MFE-23N molecules produced in mammalian
cells.
P. pastoris is widely used for the secretion of properly
folded proteins with high yields in a cost-efficient and
rapid way [21]. It offers complex posttranslational modi-
fication pathways avoiding pyrogenic contamination. In
this sense, P. pastoris holds a generally recognized as
safe (GRAS) status [22]. The yield of anti-CEA scFv-
based N-terminal trimerbody expressed in P. pastoris
was of 6 mg of pure protein per liter of culture, which is
about 20-fold higher than in mammalian cells. This is
Figure 4 Serum stability of MFE-23N purified from P. pastoris or HEK-293 cells. ELISA against plastic immobilized CEA (A) and western blot
(B) were performed after incubation at 37°C for different time periods in human serum, as indicated in material and methods.
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densities, up to 100 OD600, allowing significantly in-
creased amounts of secreted protein. P. pastoris has
been widely used in the expression of recombinant anti-
bodies, such as scFv [23,20], tandem scFvs, also known
as (scFv)2 [24], diabodies [25], Fab fragments [26-28], tri-
bodies [29], scFv-Fc [30], scFv-immunotoxins [31,32]
and full-length IgG [33,34]. Moreover, favorable protein
folding by P. pastoris seems to play a fundamental role in
the stability and activity of a single domain antibody frag-
ment against botulinum neurotoxin in comparison to the
same produced in E. coli [35]. Another relevant issue is
that P. pastoris displays both O- and N-linked glycosyla-
tion, but glycosylation patterns are different from those
found in higher eukaryotes and may lead to reduction in
activity and antigenic response. Moreover, P. pastoris is
known to glycosylate proteins that are non-glycosylated in
mammalian cells [14]. Therefore, although the prediction
of potential glycosylation sites using the GlycoEP server
[36] showed that the MFE-23N trimerbody does not con-
tain putative N- and O-glycosylation sites, we can not rule
out that yeast-produced trimerbodies may be “decorated”
with some extra sugars, and this could be the explanation
for the subtle difference in size observed between yeast-
and mammalian-produced MFE-23N molecules. Import-
antly, we have demonstrated that even if trimerbody
glycosylation takes place, it does not affect antigen bind-
ing. A current alternative is the use of the P. pastoris
genetically engineered to produce humanized glycosyla-
tion patterns. In fact, anti-Her2 mAb produced in glyco-
engineered P. pastoris exhibit features comparable
to those of trastuzumab in preclinical assays [34]. New
marketed therapeutic proteins produced in Pichia
evidence the rise of P. pastoris as a producer organism.In 2009 the FDA approved ecallantide, a small recombin-
ant protein acting as a potent, specific and reversible in-
hibitor of plasma kallikrein for the treatment of acute
hereditary angioedema [37,38].
Conclusions
Wave demonstrated that scFv-based N-terminal trimer-
bodies can be efficiently produced in P. pastoris in a tri-
meric fully functional active form. These results
illustrate the potential of Pichia pastoris for the secre-
tion of multivalent antibodies.
Methods
Reagents and antibodies
The mAb used include: C6G9 (Sigma-Aldrich, St. Louis,
MO, USA) anti-human CEA (CD66e) and Tetra-His
(Qiagen, GmbH, Hilden, Germany). The polyclonal
antibodies included: phycoerytrin (PE)-conjugated goat
F(ab’)2 fragment anti-mouse IgG (Fc fragment specific,
Jackson Immuno Research, Newmarket, UK), horserad-
ish peroxidase (HRP)-conjugated goat anti-mouse IgG
(Fc specific) (Sigma-Aldrich), and IRDye800-conjugated
donkey anti-mouse IgG (H&L) (Rockland Immunochemi-
cals, Gilbertsville, PA, USA). Human CEA was obtained
from Calbiochem (Merck, Darmstadt, Germany) and bovine
serum albumin (BSA) was from Sigma-Aldrich.
Cells and culture conditions
HEK-293 (CRL-1573) and HeLa (CCL-2) cells were ob-
tained from the American Type Culture Collection
(Rockville, MD, USA). They were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (Lonza, Walkersville,
MD, USA) supplemented with 10% (vol/vol) heat inacti-
vated fetal calf serum (FCS) (Thermo Fisher, MA, USA).
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taining 750 μg/ml G418 (Promega, Madison, WI; USA).
The methylotrophic yeast P. pastoris strain KM71 was
obtained from Invitrogen (Life Technologies, Carlsbad,
CA, USA). Cells were grown on yeast extract peptone
dextrose (YPD) plates or YPD medium at 30°C. When
harbouring an expression vector the cells were grown on
YPD plates with zeocin.
Construction of expression vectors
The mammalian expression vector pCEP4-MFE-23-
NC1ES-encoding the CEA-specific MFE-23 scFv-based
N-terminal trimerbody, containing a murine TIEXVIII
domain, has been previously reported [16]. To generate the
P. pastoris expression vector the DNA fragment encoding
the MFE-23 scFv was PCR amplified from pCEP4-MFE-
23-NC1ES- with primers EcoRI FW and NotI RV (Table 1).
The EcoRI /NotI-digested PCR fragment was ligated into
the EcoRI/NotI-digested backbone of plasmid pPICZαA
(Life Technologies) to generate the intermediate plasmid
pPICZαA-MFE-23. The DNA encoding human TIEXVIII
was PCR amplified from plasmid pCR3.1-L36-hNC1 [18]
with primers NotI FW and SalI RV (Table 1). The NotI/
SalI-digested PCR fragment was ligated into the NotI/SalI-
digested backbone of plasmid pPICZαA-MFE-23 to obtain
pPICZαA-MFE-23-TIE. The sequence was verified using
primers 5’AOX1 and 3’AOX1 (Table 1).
Stable expression in mammalian cells
HEK-293 cells were transfected with pCEP4-MFE-23-
NC1ES- vector using calcium phosphate [40], and selected
in DMEM with 150 μg/ml hygromycin B (Life Technolo-
gies) to generate stable cell lines. Supernatants from stably
transfected cell populations were analyzed for protein
expression by ELISA, SDS-PAGE and western blotting
using Tetra-His mAb.
Stable expression in yeast cells
Electrocompetent P. pastoris KM71 cells were electropo-
rated with linearized pPICZαA-MFE-23-TIE plasmid, as
previously described [31,32], using a Bio-Rad Gene pulser
apparatus (Bio-Rad, Hercules, CA, USA). Cells harboring
the desired construct were selected after plating theTable 1 Oligonucleotide sequences of the various primers ap
verification of vector sequences
Name Sequence (5′-3′)
EcoRI FW ATTTCACAGAATTC CAGGTGCA
NotI RV ATTTCACAGCGGCCGC CCGTTT
NotI FW ATTTCACAGCGGCCGC GAATTC
SalI RV ATTTCACAGTCGAC TTATTAATG
5′ AOX1 GACTGGTTCCAATTGACAAGC
3′ AOX1 GCAAATGGCATTCTGACATCCtransformation mixture on YPDS (Yeast Peptone Dextrose
Sorbitol) media containing different amounts (100 to
750 μg/ml) of zeocin (Life Technologies), and three inde-
pendent clones were tested by small-scale production.
The colony that showed better results was selected for lar-
ger scale production, which was performed by inoculating
2 l baffled flasks containing 250 ml of buffered methanol-
complex (BMMY) medium [1% yeast extract, 2% peptone,
100 m K3PO4 (pH 6.0), 1.34% yeast nitrogen base (NYD),
4.5x10−5% biotin, 0.5% methanol] for induction at 25°C
and 250 rpm shaking for 72 h. Every 24 h, methanol was
added to the medium, to afford a final methanol concen-
tration of 0.5% (v/v).
Purification
Harvested serum-free conditioned mammalian medium
was centrifuged, 0.22 μm filtered (Nalgene, Neerijse,
Belgium), concentrated (10x) with a 10.000 MWCO
Vivaflow 50 filter (Vivascience GmbH, Hannover,
Germany), dialyzed against PBS (pH7.4) and loaded onto
a HisTrap HP 1 ml column using and ÄKTA Prime plus
system (GE Healthcare, Uppsala, Sweden). The purified
trimerbody was dialyzed against PBS, analyzed by SDS-
PAGE under reducing conditions, and stored at −80°C.
Harvested yeast medium was dialyzed against 50 mM
Na3PO4 buffer, containing 100 mM NaCl (pH 8.0),
0.22 μm filtered and loaded onto a HisTrap HP 1 ml col-
umn using and ÄKTA Prime plus system. The purified
trimerbody, was dialyzed against Na3PO4 buffer, ana-
lyzed by SDS-PAGE under reducing conditions, and
stored at −80°C. For lyophilization, samples were dia-
lyzed with 50 mM (NH4)HCO3 (pH 8.0), and lyophilized
protein was stored at −20°C.
Western blotting
Samples were separated under reducing conditions on
12% Tris-glycine gels and transferred to nitrocellulose
membranes (Life Technologies) and reacted with Tetra-
His mAb, followed by incubation with an IRDye800-
conjugated donkey anti-mouse IgG. Visualization and
quantitative analysis of protein bands were carried out
with the Odyssey infrared imaging system (LI-COR Bio-
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The ability of scFv-based N-terminal trimerbodies to
bind human CEA was studied by ELISA as previously
described [16]. Briefly, Maxisorp plates (Nunc A/S,
Roskilde, Denmark) were coated with CEA (0.25 μg/
well) and after washing and blocking with 5% BSA in
PBS, 100 μl with indicated amount of purified protein or
supernatant were added for 1 hour at room temperature.
After three washes, 100 μl of Tetra-His mAb (10 μg/ml)
were added for 1 hour at room temperature. After three
washes, 100 μl of HRP-conjugated goat anti-mouse IgG
were added for 1 hour at room temperature, after which
the plate was washed and developed. Antigen titration
was performed with serial dilutions of the purified
trimerbodies.
Flow cytometry
The ability of purified antibodies to bind to cell surface
CEA was studied by FACS as described previously [16].
Briefly, cells were incubated with anti-CEA mAb (10 μg/
ml) or purified trimerbodies (10 μg/ml) and Tetra-His
mAb for 30 min. After washing, the cells were treated
with appropriate dilutions of PE-conjugated goat F(ab’)2
anti-mouse IgG. All samples were analyzed with a
Beckman-Coulter FC-500 Analyzer (Beckman-Coulter,
Brea, CA, USA).
Size exclusion chromatography-multi-angle laser light
scattering (SEC-MALLS)
Static light scattering experiments were performed at
room temperature using a Superdex 200 10/300 GL col-
umn (GE HealthCare) connected to a DAWN-HELEOS
light scattering detector and an Optilab rEX differential re-
fractive index detector (Wyatt Technology, Santa Barbara,
CA, USA). The column was equilibrated with running
buffer (PBS pH 7.0 + 0.03% NaN3, 0.1 μm filtered) and the
SEC-MALLS system was calibrated with a sample of BSA
at 1 g/l in the same buffer. Samples of 100 μl of the MFE-
23N molecules at 0.55 g/l were injected into the column at
a flow rate of 0.5 mL/min. Data acquisition and analysis
employed ASTRA software (WyattTechnology). Based on
numerous measurements on BSA samples at 1 g/l under
the same or similar conditions we estimate that the experi-
mental error in molar mass is around 5%.
Circular dichroism and thermal denaturation studies
Circular dichroism (CD) measurements were performed
with a Jasco J-810 spectropolarimeter equipped with Pel-
tier thermal control unit (Jasco, MD, USA). The spectra
were recorded at 25°C on protein samples at 0.05 g/l in
PBS using a 0.2 cm path length stoppered quartz cuvette
a response of 8 s and a band width of 2 nm. The spectra
were baseline corrected by subtraction of the buffer
spectrum recorded in same cuvette under identicalconditions. The thermal denaturations were recorded on
the same samples increasing the temperature from 10 to
95°C at a rate of 1°C/min and measuring the ellipticity at
210 nm every 1°C with a 32 second response and 4 nm
bandwidth. For the graphical representation of the melt-
ing curves of both samples the ellipticity values were
normalized from 0 (at 10°C) to 1 (at 95°C). The CD data
were processed with the program Origin (OriginLab,
MA, USA). We estimate that the uncertainty in the
molar ellipticity is about 5% and the uncertainty in the
mid-point denaturation temperature is 0.5°C.
Serum stability
One microgram of each purified scFv-based N-terminal
trimerbody was incubated in 60% human serum at 37°C
for up to 96 h. Samples were removed for analysis at 3,
24, 48 and 96 hours and frozen at −80°C until the entire
study was completed. As a control, a second set of
serum-exposed samples was frozen immediately to rep-
resent a zero time point. Aliquots were then subjected
to western blot, using Tetra-His mAb, and tested for
their capability to bind human CEA by ELISA.
Additional files
Additional file 1: Figure S1. MFE-23N secretion in HEK-293 cells and
P. pastoris. Western blot analysis of conditioned media from transfected
HEK-293 cells (A), and of culture supernatants after the induction of three
different clones (1–3) in P. pastoris (B).
Additional file 2: Figure S2. ELISA against plastic immobilized CEA
with conditioned media (MFE-23N SN) from transfected HEK-293 cells (A),
and culture supernatants after the induction of three different clones in
P. pastoris (B). In both cases MFE-23N purified (10 μg/ml) from HEK-293
cells was used as a control.
Additional file 3: Figure S3. Reducing SDS-PAGE analysis of the
samples used and separated in the SEC-MALLS experiments. Input
corresponds to the sample injected in the column and the peaks
correspond to fractions of the two peaks separated in the column. Peak1
and peak2 correspond to the peaks eluting at approximately volumes of
11 and 13 ml, respectively, as shown in Figures 3A and 3B. The total
amount of protein loaded in each lane is different because for some of
the samples eluted from the column a large volume was collected and
the total protein was precipitated before loading in the gel.
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